How did AMLX's Q4 2023 earnings surprise investors?

Amylyx Pharmaceuticals Inc. (AMLX) experienced a notable decline in its Q4 2023 earnings, which significantly surprised investors. Here are the key details: 1. **Significant Net Loss**: The company reported a substantial net loss of $37.5 million for Q4 2024, translating to a loss of $0.55 per share. This was a stark contrast to the estimated EPS of -$0.52, resulting in a surprise loss of $0.03 per share. 2. **Revenue Surpass Expectations**: Despite the net loss, Amylyx recorded revenue of $0.67 million for Q4 2024, surpassing the estimated revenue of $0.08 million. This indicated that the company's revenue exceeded expectations, which could have been a positive surprise for investors. 3. **Strategic Reduction in Spending**: Amylyx demonstrated strategic cost management by decreasing R&D expenses to $22.9 million in Q4 2024 from $44.9 million in the same period of 2023. Similarly, SG&A expenses were reduced to $17.1 million from $52.2 million. These reductions suggest a more efficient operational approach, which might have been viewed positively by investors. Overall, while the net loss might have been a negative surprise, the revenue surpassing expectations and the strategic reduction in spending could have mitigated the negative impact, presenting a complex picture of both surprises and potential optimism for investors.